Natriuretic peptide/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice

Regulatory Peptides

Volumn 154, Issue 1-3, 2009, Pages 44-53

  Nishikimi, Toshio ^a   Inaba Iemura, Chikako ^a   Ishimura, Kimihiko ^a   Tadokoro, Kazuyoshi ^a   Koshikawa, Shogo ^a   Ishikawa, Keiko ^a   Akimoto, Kazumi ^a   Hattori, Yoshiyuki ^a   Kasai, Kikuo ^a   Minamino, Naoto ^b   Maeda, Nobuyo ^c   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Atrial natriuretic peptide; cGMP; NF kappaB; Renal fibrosis; Renin angiotensin

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSINOGEN; ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLIC GMP; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR A; OSTEOPONTIN; RENIN; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MODEL; HISTOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY PARENCHYMA; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; URETER OBSTRUCTION; WILD TYPE;

ANIMALS; CROSSES, GENETIC; CYCLIC GMP; FIBROSIS; FLUORESCENT DYES; IMMUNOHISTOCHEMISTRY; INDOLES; KIDNEY DISEASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NATRIURETIC PEPTIDES; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; URETERAL OBSTRUCTION;

MUS;

EID: 63049138964     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2009.02.006     Document Type: Article

References (43)

1. Minamino N., Horio H., and Nishikimi T. Chapter 165. In: Kastin A.J. (Ed). Natriuretic peptides in the cardiovascular system, THE HANDBOOK OF BIOLOGICALLY ACTIVE PEPTIDES (2006), Academic Press 1217-1225
2. Nishikimi T., Maeda N., and Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69 (2006) 318-328
3. Lincoln T.M., Wu X., Sellak H., Dey N., and Choi C.S. Regulation of vascular smooth muscle cell phenotype by cyclic GMP and cyclic GMP-dependent protein kinase. Front Biosci 11 (2006) 356-367
4. Alexander M.R., Knowles J.W., Nishikimi T., and Maeda N. Increased atherosclerosis and smooth muscle cell hypertrophy in natriuretic peptide receptor A-/-apolipoprotein E-/- mice. Arterioscler Thromb Vasc Biol 23 (2003) 1077-1082
5. Calderone A., Thaik C.M., Takahashi N., Chang D.L.F., and Colucci W.S. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 101 (1998) 812-818
6. Fujisaki H., Ito H., Hirata Y., Tanaka M., Hata M., Lin M., Adachi S., Akimoto H., Marumo F., and Hiroe M. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 96 (1995) 1059-1065
7. Horio T., Nishikimi T., Yoshihara F., Matsuo H., Takishita S., and Kangawa K. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 35 (2000) 19-24
8. Oliver P.M., Fox J.E., Kim R., Rockman H.A., Kim H.S., Reddick R.L., Pandey K.N., Milgram S.L., Smithies O., and Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A 94 (1997) 14730-14735
9. Tamura N., Ogawa Y., Chusho H., Nakamura K., Nakao K., Suda M., Kasahara M., Hashimoto R., Katsuura G., Mukoyama M., Itoh H., Saito Y., Tanaka I., Otani H., and Katsuki M. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 97 (2000) 4239-4244
10. Anderson S., and Brenner B.M. Pathogenesis of diabetic glomerulopathy: hemodynamic considerations. Diabetes Metab Rev 4 (1988) 163-177
11. Wolf G., Thaiss F., Schoeppe W., and Stahl R.A. Angiotensin II-induced proliferation of cultured murine mesangial cells: inhibitory role of atrial natriuretic peptide. J Am Soc Nephrol. 3 (1992) 1270-1278
12. Pandey K.N., Nguyen H.T., Li M., and Boyle J.W. Natriuretic peptide receptor-A negatively regulates mitogen-activated protein kinase and proliferation of mesangial cells: role of cGMP-dependent protein kinase. Biochem Biophys Res Commun 271 (2000) 374-379
13. Kasahara M., Mukoyama M., Sugawara A., Makino H., Suganami T., Ogawa Y., Nakagawa M., Yahata K., Goto M., Ishibashi R., Tamura N., Tanaka I., and Nakao K. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol 11 (2000) 1691-1701
14. Suganami T., Mukoyama M., Sugawara A., Mori K., Nagae T., Kasahara M., Yahata K., Makino H., Fujinaga Y., Ogawa Y., Tanaka I., and Nakao K. Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J Am Soc Nephrol 12 (2001) 2652-2663
15. Makino H., Mukoyama M., Mori K., Suganami T., Kasahara M., Yahata K., Nagae T., Yokoi H., Sawai K., Ogawa Y., Suga S., Yoshimasa Y., Sugawara A., Tanaka I., and Nakao K. Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. Diabetologia 49 (2006) 2514-2524
16. Klahr S., and Purkerson M.L. The pathophysiology of obstructive nephropathy: the role of vasoactive compounds in the hemodynamic and structural abnormalities of the obstructed kidney. Am J Kidney Dis 23 (1994) 219-223
17. Bascands J.L., and Schanstra J.P. Obstructive nephropathy: insights from genetically engineered animals. Kidney Int 68 (2005) 925-937
18. Knowles J.W., Esposito G., Mao L., Hagaman J.R., Fox J.E., Smithies O., Rockman H.A., and Maeda N. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest 107 (2001) 975-984
19. Nishikimi T., Mori Y., Kobayashi N., Tadokoro K., Wang X., Akimoto K., Yoshihara F., Kangawa K., and Matsuoka H. Renoprotective effect of chronic adrenomedullin infusion in Dahl salt-sensitive rats. Hypertension 39 (2002) 1077-1082
20. Jin H., Yang R.H., Chen Y.F., Jackson R.M., and Oparil S. Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia. J Clin Invest 85 (1990) 115-120
21. Nagatoya K., Moriyama T., Kawada N., Takeji M., Oseto S., Murozono T., Ando A., Imai E., and Hori M. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 61 (2002) 1684-1695
22. Satoh M., Kashihara N., Yamasaki Y., Maruyama K., Okamoto K., Maeshima Y., Sugiyama H., Sugaya T., Murakami K., and Makino H. Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 12 (2001) 317-325
23. Nishikimi T., Koshikawa S., Ishikawa Y., Akimoto K., Inaba C., Ishimura K., Ono H., and Matsuoka H. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J Hypertens 25 (2007) 1053-1063
24. Ishikawa Y., Nishikimi T., Akimoto K., Ishimura K., Ono H., and Matsuoka H. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension 47 (2006) 1075-1083
25. Nishikimi T., Yoshihara F., Horinaka S., Kobayashi N., Mori Y., Tadokoro K., Akimoto K., Minamino N., Kangawa K., and Matsuoka H. Chronic administration of adrenomedullin attenuates transition from left ventricular hypertrophy to heart failure in rats. Hypertension 42 (2003) 1034-1041
26. Nishikimi T., Hagaman J.R., Takahashi N., Kim H.S., Matsuoka H., Smithies O., and Maeda N. Increased susceptibility to heart failure in response to volume overload in mice lacking natriuretic peptide receptor-A gene. Cardiovasc Res 66 (2005) 94-103
27. Nishikimi T., Akimoto K., Wang X., Mori Y., Tadokoro K., Ishikawa Y., Shimokawa H., Ono H., and Matsuoka H. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 22 (2004) 1787-1796
28. Ortola F.V., Ballermann B.J., Anderson S., Mendez R.E., and Brenner B.M. Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration. J Clin Invest 80 (1987) 670-674
29. Kimura K., Drozdova G., Hirata Y., Matsuoka H., Ishii M., Sugimoto T., Kangawa K., and Matsuo H. Effects of chronic administration of atrial natriuretic polypeptide on glomerular lesions in spontaneously hypertensive rats. Jpn Heart J 31 (1990) 227-236
30. Sakamoto K., Kikkawa R., Haneda M., and Shigeta Y. Prevention of glomerular hyperfiltration in rats with streptozotocin-induced diabetes by an atrial natriuretic peptide receptor antagonist. Diabetologia 38 (1995) 536-542
31. Klahr S., and Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 283 (2002) F861-F875
32. Morrissey J.J., Ishidoya S., McCracken R., and Klahr S. The effect of ACE inhibitors on the expression of matrix genes and the role of p53 and p21 (WAF1) in experimental renal fibrosis. Kidney Int 54 (1996) S83-S87
33. Ishidoya S., Morrissey J., McCracken R., Reyes A., and Klahr S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47 (1995) 1285-1294
34. Chevalier R.L. Growth factors and apoptosis in neonatal ureteral obstruction. J Am Soc Nephrol 7 (1996) 1098-1105
35. Vellaichamy E., Kaur K., and Pandey K.N. Enhanced activation of pro-inflammatory cytokines in mice lacking natriuretic peptide receptor-A. Peptides 28 (2007) 893-899
36. Moriyama N., Taniguchi M., Miyano K., Miyoshi M., and Watanabe T. ANP inhibits LPS-induced stimulation of rat microglial cells by suppressing NF-kappaB and AP-1 activations. Biochem Biophys Res Commun 350 (2006) 322-328
37. Kiemer A.K., Weber N.C., and Vollmar A.M. Induction of IkappaB: atrial natriuretic peptide as a regulator of the NF-kappaB pathway. Biochem Biophys Res Commun 295 (2002) 1068-1076
38. Tsukagoshi H., Shimizu Y., Kawata T., Hisada T., Shimizu Y., Iwamae S., Ishizuka T., Iizuka K., Dobashi K., and Mori M. Atrial natriuretic peptide inhibits tumor necrosis factor-α production by interferon-gamma-activated macrophages via suppression of p38 mitogen-activated protein kinase and nuclear factor-kappa B activation. Regul Pept 99 (2001) 21-29
39. Rosón M.I., Toblli J.E., Della Penna S.L., Gorzalczany S., Pandolfo M., Cavallero S., and Fernández B.E. Renal protective role of atrial natriuretic peptide in acute sodium overload-induced inflammatory response. Am J Nephrol 26 (2006) 590-601
40. Ladetzki-Baehs K., Keller M., Kiemer A.K., Koch E., Zahler S., Wendel A., and Vollmar A.M. Atrial natriuretic peptide, a regulator of nuclear factor-kappaB activation in vivo. Endocrinology 148 (2007) 332-336
41. Fern R.J., Yesko C.M., Thornhill B.A., Kim H.S., Smithies O., and Chevalier R.L. Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice. J Clin Invest 103 (1999) 39-46
42. Lai F.J., Hsieh M.C., Hsin S.C., Lin S.R., Guh J.Y., Chen H.C., and Shin S.J. The cellular localization of increased atrial natriuretic peptide mRNA and immunoreactivity in diabetic rat kidneys. J Histochem Cytochem 50 (2002) 1501-1508
43. Shin S.J., Wen J.D., Chen I.H., Lai F.J., Hsieh M.C., Hsieh T.J., Tan M.S., and Tsai J.H. Increased renal ANP synthesis, but decreased or unchanged cardiac ANP synthesis in water-deprived and salt-restricted rats. Kidney Int 54 (1998) 1617-1625